• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Arbutus Biopharma Corporation

    6/5/26 4:05:30 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABUS alert in real time by email
    S-8 1 a2026s-8form.htm S-8 Document

    As filed with the Securities and Exchange Commission on June 5, 2026
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933
    Arbutus Biopharma Corporation
    (Exact name of registrant as specified in its charter)
    British Columbia, Canada98-0597776
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    701 Veterans Circle
    Warminster, Pennsylvania
    18974
    (Address of Principal Executive Offices)(Zip Code)
    Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan

    (Full title of the plan)

    Tuan Nguyen
    Chief Financial Officer
    Arbutus Biopharma Corporation
    701 Veterans Circle
    Warminster, Pennsylvania 18974
    (Name and address of agent for service)
    (267) 469-0914
    (Telephone number, including area code, of agent for service)
    With Copies to:
    Steven J. Abrams, Esq.
    Stephen M. Nicolai, Esq.
    Hogan Lovells US LLP
    1735 Market Street, 23rd Floor
    Philadelphia, PA 19103
    (267) 675-4600
    Andrew Sung
    General Counsel
    Arbutus Biopharma Corporation
    701 Veterans Circle
    Warminster, Pennsylvania 18974
    (267) 469-0914

    R. Hector MacKay-Dunn, K.C.
    Farris LLP
    2500-700 West Georgia Street
    Vancouver, British Columbia
    Canada V7Y 1B3
    (604) 684-9151



    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer
    Accelerated filer
    Non-accelerated filer
    Smaller reporting company
    Emerging growth company
    ☐
    ☐
    ☒
    ☒
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐













































    EXPLANATORY NOTE

    This registration statement on Form S-8 (this “Registration Statement”) is being filed by Arbutus Biopharma Corporation (the “Registrant”) to register 16,300,000 common shares of the Registrant, without par value (the “Common Shares”), reserved for issuance under the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan (the “2026 Plan”). The Board of Directors of the Registrant approved the 2026 Plan on April 10, 2026, and the Registrant’s shareholders approved the 2026 Plan at the Registrant’s 2026 Annual General and Special Meeting of Shareholders on May 26, 2026.
    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

    As permitted by the rules of the Securities and Exchange Commission (the “Commission”), the information specified in Part I of Form S-8 is omitted from this Registration Statement. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.    Incorporation of Documents by Reference.

    The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:

    (a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 23, 2026;

    (b)    the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Commission on May 13, 2026;

    (c)    the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 14, 2026, to the extent incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025;

    (d)    the Registrant’s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed with the Commission on January 16, 2026, February 6, 2026, February 20, 2026, March 3, 2026, April 15, 2026, and May 27, 2026; and

    (e)    the description of the Common Shares contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-34949) filed with the Commission on November 4, 2010, as updated by Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including any amendments or reports filed for the purpose of updating such description.

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for the documents and reports, or portions thereof, that are “furnished” rather than filed with the Commission.

    For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or



    supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4.    Description of Securities.

    Not applicable.

    Item 5.    Interests of Named Experts and Counsel.

    Not applicable.

    Item 6.    Indemnification of Directors and Officers.

    The Registrant is subject to the provisions of Part 5, Division 5 of the British Columbia Business Corporations Act (the “Act”).

    Under Section 160 of the Act, the Registrant may, subject to Section 163 of the Act, do one or both of the following:

    (1)indemnify an individual who:

    •is or was a director or officer of the Registrant;

    •is or was a director or officer of another corporation (i) at a time when such corporation is or was an affiliate of the Registrant; or (ii) at the Registrant’s request, or

    •at the Registrant’s request, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity,

    and includes, subject to certain limited exceptions, the heirs and personal or other legal representatives of that individual (collectively, an “eligible party”), against all eligible penalties to which the eligible party is or may be liable; and

    (2)     after final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, where:

    •“eligible penalty” means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding.

    •“eligible proceeding” means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Registrant or an associated corporation (a) is or may be joined as a party, or (b) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding.

    •“proceeding” includes any legal proceeding or investigative action, whether current, threatened, pending or completed.

    Under Section 161 of the Act, and subject to Section 163 of the Act, the Registrant must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding if the eligible party (a) has not been reimbursed for those expenses, and (b) is wholly successful, on the merits or otherwise, in the outcome of the proceeding or is substantially successful on the merits in the outcome of the proceeding.

    Under Section 162 of the Act, and subject to Section 163 of the Act, the Registrant may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of the proceeding, provided that the Registrant must not make such payments unless the Registrant first receives from
    3


    the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited under Section 163 of the Act, the eligible party will repay the amounts advanced.

    Under Section 163 of the Act, the Registrant must not indemnify an eligible party against eligible penalties to which the eligible party is or may be liable or pay the expenses of an eligible party in respect of that proceeding under Sections 160, 161 or 162 of the Act, as the case may be, if any of the following circumstances apply:

    •if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses was made, the Registrant was prohibited from giving the indemnity or paying the expenses by the Registrant’s Notice of Articles and Articles, as amended (the “Articles”);

    •if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, the Registrant is prohibited from giving the indemnity or paying the expenses by the Articles;

    •if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of the Registrant or the associated corporation, as the case may be; or

    •in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party’s conduct in respect of which the proceeding was brought was lawful.

    If an eligible proceeding is brought against an eligible party by or on behalf of the Registrant or by or on behalf of an associated corporation, the Registrant must not either indemnify the eligible party against eligible penalties to which the eligible party is or may be liable, or pay the expenses of the eligible party under Sections 160, 161 or 162 of the Act, as the case may be, in respect of the proceeding.

    Under Section 164 of the Act, and despite any other provision of Part 5, Division 5 of the Act and whether or not payment of expenses or indemnification has been sought, authorized or declined under Part 5, Division 5 of the Act, on application of the Registrant or an eligible party, the Supreme Court of British Columbia may do one or more of the following:

    •order the Registrant to indemnify an eligible party against any liability incurred by the eligible party in respect of an eligible proceeding;

    •order the Registrant to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding;

    •order the enforcement of, or payment under, an agreement of indemnification entered into by the Registrant;

    •order the Registrant to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order under Section 164 of the Act; or

    •make any other order the court considers appropriate.

    Section 165 of the Act provides that the Registrant may purchase and maintain insurance for the benefit of an eligible party or the heirs and personal or other legal representatives of the eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Registrant or an associated corporation.

    4


    Under the Articles, and subject to the Act, the Registrant must indemnify an eligible party and his or her heirs and legal personal representatives against all eligible penalties to which such person is or may be liable, and the Registrant must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. Each eligible party is deemed to have contracted with the Registrant on the terms of the indemnity contained in the Articles.

    Under the Articles, and subject to the Act, the Registrant may agree to indemnify and may indemnify any person (including an eligible party) against eligible penalties and pay expenses incurred in connection with the performance of services by that person for the Registrant.

    Under the Articles, and subject to the Act, the Registrant may advance expenses to an eligible party.

    Pursuant to the Articles, the failure of an eligible party to comply with the Act or the Articles does not, of itself, invalidate any indemnity to which he or she is entitled under the Articles.

    Under the Articles, the Registrant may purchase and maintain insurance for the benefit of an eligible person (or his or her heirs or legal personal representatives) against any liability incurred by him or her as a director, officer or person who holds or held such equivalent position.

    The Registrant has entered into indemnity agreements with its directors and executive officers. In general, these agreements provide that the Registrant will indemnify the director or executive officer for claims arising in his or her capacity as a director or officer of the Registrant or in connection with their service at the Registrant’s request for another corporation or entity. The indemnity agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is therefore unenforceable.

    Item 7.    Exemption from Registration Claimed.

    Not applicable.



    5


    Item 8.    Exhibits.

    Exhibit
    Number

    Description
    4.1
    Notice of Articles and Articles of the Registrant, as amended (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Commission on March 16, 2018).
    4.2
    Amendment to Articles of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the Commission on November 7, 2018).
    4.3
    Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on May 27, 2026).
    5.1*
    Opinion of Farris LLP.
    23.1*
    Consent of Ernst and Young, LLP, Independent Registered Public Accounting Firm.
    23.2*
    Consent of Farris LLP (included in Exhibit 5.1).
    24.1
    Power of Attorney (included in signature page to this Registration Statement).
    107*
    Filing Fee Table.

    *Filed herewith.

    Item 9.    Undertakings.

    (a)
    The undersigned Registrant hereby undertakes:
    (1)
    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i)
    to include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)
    to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and
    (iii)
    to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
    (2)
    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    6


    (b)
    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c)
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    7



    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the Township of Warminster, Commonwealth of Pennsylvania, on June 5, 2026.
    ARBUTUS BIOPHARMA CORPORATION
    By:/s/ Lindsay Androski
    Lindsay Androski
    President and Chief Executive Officer

    POWER OF ATTORNEY

    We, the undersigned officers and directors of Arbutus Biopharma Corporation, hereby severally constitute and appoint Lindsay Androski and Tuan Nguyen, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Arbutus Biopharma Corporation to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ Lindsay AndroskiPresident and Chief Executive Officer and DirectorJune 5, 2026
    Lindsay Androski(Principal Executive Officer)
    /s/ Tuan NguyenChief Financial OfficerJune 5, 2026
    Tuan Nguyen(Principal Financial Officer and Principal Accounting Officer)
    /s/ Robert Alan BeardsleyChairmanJune 5, 2026
    Robert Alan Beardsley
    /s/ Joseph BishopDirectorJune 5, 2026
    Joseph Bishop
    /s/ Matthew GlineDirectorJune 5, 2026
    Matthew Gline
    /s/ Dr. Roger SawhneyDirectorJune 5, 2026
    Dr. Roger Sawhney






    8


    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of the Registrant, has signed this Registration Statement on June 5, 2026.

    By:/s/ Lindsay Androski
    Lindsay Androski
    President and Chief Executive Officer
    9
    Get the next $ABUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABUS

    DatePrice TargetRatingAnalyst
    3/4/2022$5.50 → $6.00Buy
    Chardan Capital
    2/2/2022$4.00 → $5.00Hold → Buy
    Jefferies
    11/8/2021$7.00 → $9.00Market Outperform
    JMP Securities
    More analyst ratings

    $ABUS
    SEC Filings

    View All

    SEC Form S-8 filed by Arbutus Biopharma Corporation

    S-8 - Arbutus Biopharma Corp (0001447028) (Filer)

    6/5/26 4:05:30 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Biopharma Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Arbutus Biopharma Corp (0001447028) (Filer)

    5/27/26 4:01:33 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Arbutus Biopharma Corporation

    10-Q - Arbutus Biopharma Corp (0001447028) (Filer)

    5/13/26 7:31:46 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Nguyen Tuan was granted 73,500 shares (SEC Form 4)

    4 - Arbutus Biopharma Corp (0001447028) (Issuer)

    2/2/26 8:21:34 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Androski Lindsay was granted 28,000 shares (SEC Form 4)

    4 - Arbutus Biopharma Corp (0001447028) (Issuer)

    2/2/26 8:21:13 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sawhney Roger

    4 - Arbutus Biopharma Corp (0001447028) (Issuer)

    8/6/25 4:08:29 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on Arbutus Biopharma with a new price target

    Chardan Capital reiterated coverage of Arbutus Biopharma with a rating of Buy and set a new price target of $6.00 from $5.50 previously

    3/4/22 8:38:50 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Biopharma upgraded by Jefferies with a new price target

    Jefferies upgraded Arbutus Biopharma from Hold to Buy and set a new price target of $5.00 from $4.00 previously

    2/2/22 5:11:07 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities reiterated coverage on Arbutus Biopharma with a new price target

    JMP Securities reiterated coverage of Arbutus Biopharma with a rating of Market Outperform and set a new price target of $9.00 from $7.00 previously

    11/8/21 7:11:01 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

    Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update. LNP Litigation On March 3, 2026, Arbutus, along wit

    5/13/26 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

    Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B ("cHBV"). "We are excited about the potential of imdusiran, which in trials has achieved functional cure for 10 chronic hepatitis B patients to date and allowed many others to live medication-free, to address significant unmet medica

    4/15/26 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

    Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents significant outcome for Arbutus and Genevant Two additional patients from Phase 2a clinical trials of imdusiran achieve functional cure Milestone payment received under Alnylam LNP license for product candidate to treat hepatocellular carcinoma (HCC) WARMINSTER, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today reported fourth q

    3/23/26 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arbutus Biopharma Corporation

    SC 13G/A - Arbutus Biopharma Corp (0001447028) (Subject)

    11/14/24 8:41:06 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Arbutus Biopharma Corporation

    SC 13G - Arbutus Biopharma Corp (0001447028) (Subject)

    6/10/24 4:50:25 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Arbutus Biopharma Corporation (Amendment)

    SC 13D/A - Arbutus Biopharma Corp (0001447028) (Subject)

    5/17/24 9:03:23 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Leadership Updates

    Live Leadership Updates

    View All

    Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

    Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer Strong financial position with cash, cash equivalents and investments in marketable securities of $123M WARMINSTER, Pa., March 27, 2025 (GLO

    3/27/25 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

    WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company's Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company's board of directors. Ms. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She

    2/25/25 7:00:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

    WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that after a distinguished 38-year career, the Company's co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024. Dr. Sofia is a globally recognized, Lasker award-winning antiviral drug discovery and development scientist. "On behalf of the entire Company, I want to thank Mike, a renowned industry veteran, for his tremendous contribu

    5/2/24 7:25:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Financials

    Live finance-specific insights

    View All

    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

    Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva

    3/3/26 4:15:00 PM ET
    $ABUS
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

    Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva

    3/3/26 4:15:00 PM ET
    $ABUS
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2026Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a f

    11/6/24 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care